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Abstract: microRNAs are post-transcriptional regulators of gene expression that have 
been shown to be central players in the establishment of cellular programs, often acting as 
switches that control the choice between proliferation and differentiation during 
development and in adult tissues. The heart develops from two small patches of cells in the 
mesoderm, the heart fields, which originate the different cardiac cell types, including 
cardiomyocytes, vascular smooth muscle and endothelial cells. These progenitors 
proliferate and differentiate to establish a highly connected three-dimensional structure, 
involving a robust succession of gene expression programs strongly influenced by 
microRNAs. Although the mammalian heart has conventionally been viewed as a post-
mitotic organ, cardiac cells have recently been shown to display some regenerative 
potential, which is nonetheless insufficient to regenerate heart lesions, in contrast with 
other vertebrates like the zebrafish. Both the proliferation of adult cardiac stem cells and 
the ability of cardiomyocytes to re-enter the cell cycle have been proposed to sustain 
these regenerative processes. Here we review the role of microRNAs in the control of 
stem cell and cardiomyocyte dependent cardiac regeneration processes, and discuss 
potential applications for the treatment of cardiac injury. 
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1. Introduction 
The recent emergence of new sequencing technologies has significantly changed our understanding 
of the organization of eukaryotic genomes, providing exciting insights into the role of non-coding (nc) 
DNA sequences. Previously known as “junk DNA” [1], these ubiquitous entities are now 
acknowledged to play critical roles in the regulation of gene expression and, not surprisingly, there is 
increasing evidence that directly correlates their relative abundance to the complexity of higher 
organisms [2–5]. It is now clear that over 90% of the human genome is transcribed generating a wide 
variety of non-coding transcripts (around 9.000 small-ncRNAs, 10.000-32.000 long-ncRNAs and 
about 11.000 pseudogenes [6,7]) that vastly exceed the number of coding transcripts (21.000 coding 
genes). The relevance of the non-coding transcriptome in the complex regulatory networks that 
contribute to tissue homeostasis and organismal complexity is becoming increasingly apparent. Several 
studies have uncovered critical roles of the ncRNome since they act as master regulators of cell fate 
and function at all levels, from epigenetic control to mRNA translation and cell-to-cell 
communication. Non-coding transcripts can be classified into two major classes based on their relative 
size. Among the small non-coding RNAs, microRNAs (miRNAs or miRs), a class of 21 to 24 
nucleotide (nt) long ncRNAs, stand out as one of the best characterized families, with the current count 
for the human genome standing at 2588 mature miRs in the latest version of miRbase (v21) [8]. It is 
likely that the known diversity of this family will continue to increase, as attested by the recently 
reported discovery of 2469 novel human miRNA candidates [9], although for a vast majority of 
annotated miRNAs their functional relevance remains unclear. Nevertheless, this repertoire is 
believed to greatly enhance the complexity of the regulatory layers that control temporal and spatial 
gene expression.  
Like many other organismal processes, mammalian heart development and homeostasis have been 
increasingly shown to be tightly regulated by miRNAs. However, unlike other mammalian organs or 
the heart of lower vertebrates, the mammalian heart displays very little regenerative abilities. Cardiac 
dysfunction resulting from myocardium cell death, as in aging or myocardial infarction, is therefore a 
major health problem in urgent need of new therapeutic solutions. During the past decade, several 
studies have come to suggest that the potential for cardiac regeneration may still be present, albeit 
silenced, in the mammalian heart [10–12]. Therefore, novel insights into the role of the tiny molecular 
switches that can play determinant roles in cardiac cell proliferation and differentiation are of great 
relevance, not only to complement the current understanding of heart biology, but also to open new 
windows for the development of innovative strategies to treat several cardiac-related pathologies.  
In this review, we will focus on the role of miRNAs as master regulators of cardiac development, 
cell fate and proliferation and discuss how recent advances in our understanding of the heart’s 
structure and function as well as novel discoveries in the field of cell fate reprogramming are 
bringing these small molecules to the forefront of regenerative therapies for heart injury. A related 
field with high potential for cardiac repair – cell therapy involving the transplantation and in situ 
differentiation of stem cells [13,14]—in which miRNAs play a relevant role as modulators of both 
pluripotency and differentiation [15], will not be discussed here in detail.  
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2. Regulatory Programs Underlying Heart Development 
Organ formation involves the sequential deployment of gene regulatory events that define cell fate 
by influencing proliferation and differentiation, while determining their physical arrangement into  
well-defined structures. The underlying regulatory programs need to coordinate the multiple 
dimensions of the process by defining the appropriate timing, spatial organization and feedback 
controls that are required to ensure the canalization of developmental processes. During the past 
decade, a significant progress in our understanding of evolutionary, developmental and genetic 
processes coordinating mammalian heart development has been achieved. More recently, microRNAs 
have been shown to be an integral part of these regulatory layers, thereby acting as key regulators of 
organ development.  
2.1. Transcriptional Networks in Embryonic Heart Development 
The development of the mammalian heart is a relatively well-characterized paradigm of the 
establishment of such regulatory programs. Although often misconstrued as a simple muscular pump, 
the heart is in fact a complex organ in which several cell types—including cardiac and smooth muscle, 
endothelial and pacemaker cells—are integrated into a highly interconnected three-dimensional 
structure. A decade of studies has unraveled to significant detail the transcriptional networks that 
control heart development, with particular emphasis on the mechanisms underlying skeletal 
myogenesis. The current model identifies a primordial core of myogenic transcription factors—MEF2 
and NK2—that became involved in the regulation of muscle-specific gene expression early during the 
evolution of animals (reviewed by [16]). With the appearance of the bilateria, these genes became 
integrated in a cardiogenic network with additional transcription factors—GATA, Tbx, and  
Hand—that evolved to regulate both cardiogenic differentiation, including the expression of contractile 
proteins, and the morphogenesis of simple cardiac structures [16]. The appearance of a  
multi-chambered, asymmetric heart was marked by duplications and specializations of several of these 
genes, in association with the appearance of complex morphogenetic patterns that lead to the formation 
of the organ during development. For example, the two ancestral GATA genes present in the bilateria 
(GATA1/2/3 and GATA4/5/6) gave rise to a total of six genes (GATA1 to 6) as a consequence of the 
genome duplication events that occurred during vertebrate evolution [17]. Of these, GATA4, GATA5 
and GATA6 have been shown to the be expressed in the heart and to be implicated in heart 
development [16]. Of note, the evolutionary retention of all these paralogous genes is quite 
remarkable, as a comparative study between the amphioxus and the human genome suggests that 
only about ¼ of the human genes correspond to duplicated genes, with a much smaller fraction 
showing the retention of multiple paralogs [18]. Therefore, the expansion of the cardiogenic 
transcriptional machinery must have been supported by a strong evolutionary pressure, likely related to 
its critical role in the development of an increasingly complex heart. By week 8 of human 
development, this highly coordinated morphogenetic program will have lead to the establishment of 
the basic heart structure. During the period of time that follows until birth, heart development will 
focus on an unparalleled increase in size. In humans, this means the heart will become roughly 10000× 
larger than its mouse counterpart, involving a much longer developmental time frame (several weeks, 
Cells 2014, 3 999 
 
compared to 48h). Recent studies suggest that this is achieved by a ‘stem cell’ based mechanism rather 
than by division of differentiated cell types [19,20]. 
2.2. A Stem Cell Model for Heart Development 
The pluripotent stem cell paradigm for heart development has been established from multiple lines 
of evidence. Lineage tracing in developmental models have clearly shown that the myocardium, with 
all its different cell types, is formed primarily from two patches of mesoderm present in the early 
embryo, termed the first and second heart fields (FHF and SHF), which deploy slightly different gene 
expression programs during development (reviewed by [20]). Cells from the SHF will contribute to 
over 70% of the myocardium, whereas the FHF is the only source of cells for the left ventricle (see 
below). Two additional embryonic regions, the cardiac neural crest and the proepicardium have also 
been shown to provide smaller contributions to the heart structure. The first gives rise to the vascular 
smooth muscle of the aortic arch, ductus arteriosus and the great vessels and essential components of 
the cardiac autonomic nervous system, while the second generates the epicardium tissue that surrounds 
the heart and contributes to the coronary vasculature, as well as providing an additional source for 
cardiomyocytes [21].  
Figure 1. A stem cell model for heart development. The heart is composed of different cell 
types that are generated from multipotent cardiac progenitors. Expression of the  
LIM-homeodomain transcription factor Islet-1 (Isl-1+) is a hallmark of these cardiac 
progenitors. The diversification of heart cell lineages is acknowledged to be controlled by 
several miRNAs.  
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Although the full details of the specification of cellular lineages that compose the heart remain to be 
worked out, several lines of evidence support the view that the process follows the same logic as the 
development of the hematopoietic system, in which a multipotent progenitor gives rise to the different 
specialized cell types through successive steps of lineage commitment (Figure 1). The expression of 
different transcriptional activators and downstream target genes along this differentiation series 
highlights the underlying regulatory programs that contribute to cardiac cell fate decisions [20]. 
Interestingly, the past few years have revealed that miRNAs (and other non-coding RNAs) are highly 
integrated into these regulatory programs, contributing to the definition of cardiac cell fate as well as 
to all other dimensions of heart development and function. 
2.3. Postnatal Heart Development 
After birth a significant reorganization of mammalian heart structure will take place as an 
adaptation to the changes in blood circulation and functional requirements for adult heart function. 
This reorganization involves macroscopic alterations in the heart structure and at the same time a 
significant remodeling of cardiomyocyte gene expression programs, leading to a transition from fetal 
to adult genes and protein isoforms that affects cell structures and functions as diverse as contractile 
fibers and energy producing pathways. This switch occurs concomitant with the almost complete 
cessation of cellular proliferation [22,23]. Accordingly, the mammalian heart loses most of its 
regenerative capacities not long after birth, dealing with stress and damage mostly through 
hypertrophy of pre-existing cardiomyocytes, fibroblast accumulation and scarring. Interestingly, while 
these responses seem to involve the re-enactment of parts of the fetal heart program they often result 
severe contractile dysfunction, to the point of heart failure. The regulatory mechanisms underlying the 
fetal to adult switch and conversely the switch to fetal expression profiles upon injury, are only 
beginning to be understood, but are of extreme importance for understanding the mechanisms that 
control heart regeneration and response to injury. As with other aspects of heart development, these 
switches have been recently shown to be under the influence of miRNAs. Understanding the 
mechanisms of biogenesis and mode of action of these molecules is therefore critical to an in-depth 
knowledge of many of the molecular events underlying cardiac function and repair. 
3. microRNAs: from Biogenesis to Post-Transcriptional Control of Gene Expression 
miRNA biogenesis is acknowledged to be regulated either at transcriptional [24] or post-
transcriptional level [25]. During the past few years, significant progress was made regarding the 
systematic identification of miRNA genes, understanding of their organization and of the biogenesis 
mechanisms required for their synthesis and basic modes of action. It is, however, clear that many of 
these processes are only understood in a relatively superficial manner, and the diversity of mechanisms 
that have increasingly been discovered suggests that there is still much to be learnt about these small 
molecules. 
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3.1. microRNA Gene Structure 
Figure 2. Overview of the miRNA biogenesis pathway. miRNA genes are transcribed in 
the nucleus by RNA Pol II as long pri-miRNA transcripts that are 5′ capped and 3′ 
polyadenylated. The pri-miRNA sequence folds into a hairpin loops structure that is 
recognized and processed by the Microprocessor complex Drosha-DGCR8, generating a  
pre-microRNA. Mirtrons, a class of unconventional miRNAs, are encoded in small introns 
and do not require Drosha processing. The intron lariat excised by the spliceosome is 
refolded into a pre-miRNA hairpin loop. The pre-miRNA is exported from the nucleus to 
the cytoplasm by exportin 5 (XPO5), where is further cropped by Dicer in complex with 
TRBP, yielding a ~22 nt double-stranded RNA called miRNA/miRNA* duplex. The 
functional mature miRNA is loaded together with Argonaute proteins into the RISC 
complex, guiding RISC to silence a target mRNA through translational repression or 
deadenylation. The biogenesis pathway of miRNAs are post-transcriptionally controlled by 
RNA editing. A-to-I editing of the miRNA’s precursors, a reaction catalyzed by ADAR 
enzymes, can block Drosha and Dicer processing, and thereby regulates the availability of 
mature miRNA in the cell. Competing endogenous RNAs (ceRNAs) can regulate mRNA 
expression levels by competing for shared miRNA binding sites.  
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With very few exceptions [26,27], miRNA genes are initially transcribed in the nucleus by the RNA 
polymerase II as long 5′-capped and Poly-A tailed pri-miRNA precursors, which fold into hairpin 
structures that are recognized by the miRNA biogenesis machinery (Figure 1) [28,29]. Based on their 
genomic localization, pri-miRNAs can be transcribed either from intergenic or intragenic genomic 
environments. The majority of mammalian miRNA genes are located either in introns of protein-
coding genes or as independent non-coding transcriptional units (TUs) [30]. Within both groups, some 
miRs are organized into clusters transcribed as polycistronic TUs (ranging from 2 to 19 miRNA 
hairpins in tandem) that, upon processing by the miRNA biogenesis machinery generate multiple 
mature miRNAs (Figure 2A). Although initially believed to be co-transcribed and co-expressed with 
their host genes under the transcriptional control of the host gene promoter [30], several studies 
indicate that some intronic miRNA genes may not follow this rule, relying on an additional layer of 
transcriptional control by their own independent promoters [31,32]. A subset of intronic miRNA genes 
that are transcribed in an anti-sense orientation with respect to their host gene were also found to have 
specific cis-regulatory elements and thus not to depend directly on host gene expression [33,34]. Despite 
the complexity involving the identification of miRNA genes promoters and putative transcription factors 
binding sites [35], independent intronic promoters are acknowledged to be an important functional 
feature that allows miRNA expression levels to be controlled in a tissue- or development-specific 
fashion [36]. Furthermore, intronic miRs do not seem to depend on splicing of their host intron for 
removal [37]. 
3.2. The microRNA Biogenesis Machinery 
Upon transcription, pri-miRNAs are submitted to two sequential processing events that trim the 
transcript in order to yield a mature miRNA. Within the nucleus, pri-miRNAs are cropped into a  
60–100nt hairpin-structured precursor (the pre-miRNA) by a multiprotein Microprocessor complex 
that includes the RNAase III Drosha and the DGCR8 (DiGeorge syndrome Critical Region 8) protein, 
as well as several auxiliary cofactors that coordinate activity and specificity of Drosha cleavage  
(for review see [25]). Binding of DGCR8 to the pri-miRNA allows precise positioning and orientation 
of Drosha’s catalytic center ~11nt upstream of the stem-loop, in order to generate a double-stranded  
pre-miRNA with a 2 nt 3' overhang [38]. After nuclear processing, the pre-miRNA is exported to the 
cytoplasm by Exportin-5 (XPO5) via a RAN-GTP dependent mechanism [39,40]. Efficient recognition 
by XPO5, defined not only by the length of the double stranded stem but also by the 3'overhangs, 
protects pre-miRs from degradation, allowing exporting of only correctly processed miRNA 
precursors [41,42]. In the cytoplasm, the pre-miRNA is further cleaved near the terminal loop by 
Dicer, another RNAse III enzyme that, together with TAR RNA binding protein (TRBP), protein 
kinase RNA activator (PACT) and Argonaute (Ago) proteins, forms the RNA induced silencing 
complex (RISC) [43–45]. Dicer is considered to act as a molecular ruler, cleaving the pre-miRNA at a 
specific distance from the ends produced by Drosha and generating a ~22nt double-stranded miRNA 
duplex (miR/miR*) with a 2 nt 3' overhang (Figure 2). The RISC complex incorporates one of the 
strands of the diced miRNA duplex, generally the one with the lowest base-pairing stability at the  
5' end, while the other strand, originally termed miR*, is degraded. There are however many instances 
where both strands can be found as part of miR-RISC complexes, albeit at different frequencies (which 
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may be as high as 100:1) [46]. In this case, the two miRNA strands arising from the same precursor are 
termed -5p or -3p, depending on their relative position in the hairpin sequence (Figure 3B).  
Figure 3. miRNA genomic organization and pre-miRNA hairpin loop features. (A) 
Mammalian miRNA genes are encoded in defined transcription units (TUs) that based on 
their genomic localization can be classified into three major groups: (i) intronic miRNA 
genes in protein-coding genes; (ii) intergenic miRNA genes; (iii) intronic miRNA genes in  
non-coding TUs. miRNA genes can be clustered in a single polycistronic transcript that 
can be processed in order to generate two or more mature miRNAs. Some miRNA genes 
are located within TUs with the same transcription orientation as the host gene, whereas 
others can be transcribed in the anti-sense orientation. (B) miRNA precursors fold into a 
hairpin loop structure that is sequentially processed. Drosha cleaves the pri-miRNA at the 
base of the stem-loop, generating a pre-miRNA (~70 nt long) precursor that is further 
processed by Dicer in order to produce a miRNA double-stranded duplex (~22 nt). Both 
Drosha and Dicer processing generates a characteristic 2 nt 3'overhang. Depending on the 
relative localization in the hairpin-loop, the mature miRNA can be termed -5p or -3p.  
 
Although the vast majority of miRs follow the canonical biogenesis pathway, a small subset has 
been shown to bypass some steps. Mirtrons, a group of unconventional miRs, are processed by the 
spliceosome and do not rely on Drosha to generate pre-miRNA precursors [47]. There are also mirtron-
like splicing-independent miRNAs, termed simtrons, which are processed by Drosha and do not 
require DGCR8 nor Dicer for their biogenesis [48]. Additionally, processing of some small nucleolar 
RNAs (snoRNAs), transfer RNAs (tRNAs) and endogenous short hairpin RNAs (shRNAs) is also reported 
to generate miRNA-like molecules that are independent of the Microprocessor complex [49–51].  
Regulation of miRNA biogenesis is also reported to be post-transcriptionally controlled through 
RNA editing of miRNA transcripts by Adenosine Deaminases that act on RNA (ADARs). These 
enzymes catalyze the conversion of adenosine (A) into inosine (I). A-to-I editing of some miRNA 
precursors not only controls several steps of the biogenesis pathway, from blocking Drosha-DGCR8 
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cleavage to inhibition of the Dicer-TRBP complex, but may also redirect mRNA target  
recognition [52–56]. However, a recent report shows that ADAR1 and Dicer directly interact in 
protein-protein complexes that, independently of the deaminase activity, promote pre-miRNA cleavage 
by Dicer and facilitate miRNA loading into the RISC [57]. Although many questions remain to be 
answered, RNA editing is currently acknowledged as an effective post-transcriptional mechanism that 
regulates miRNA biogenesis and activity. 
3.3. microRNA Modes of Action 
The mature miRNA incorporated into RISC interacts with the mRNA through Watson-Crick 
complementary base-pairing that most frequently occurs at the 3' UTR, although some can bind the 5' 
UTR [58]. The mRNA-miRNA base-pairing interaction is primarily determined by the so called  
‘seed-sequence’, a 7 nt stretch located at positions 2 to 8 of the mature miRNA. Target cleavage is 
generally associated with full complementarity with the full miRNA sequence, a rarely observed event 
in animals, where miRNA target sites are generally classified into two categories: 5' dominant, which 
base-pair precisely with the seed with or without additional involvement of 3' nucleotides; and 3' 
compensatory sites, in which the base pairing of 3' miRNA nucleotides is required to compensate for 
insufficient seed complementarity [46]. miRs that share the same seed sequence are often defined as a 
‘family’. In many cases, these miRNAs arise from paralogous genes. Examples include the let-7 family, 
which contains the first miRNA to ever be described [59] or the miR-1/133 and miR-15 families.  
Binding of the RISC complex to a mRNA generally results in a down regulation of target gene 
expression, either through ‘dicing’ of the mRNA (endonucleolytic cleavage), which is relatively rare in 
animals, or translation inhibition and degradation through decapping and deadenylation [60]. 
Translation inhibition may occur in a reversible fashion, often associated to the accumulation of the 
mRNA-miRNA-RISC complex in cellular structures termed P-bodies [46]. Quantitative proteomic 
analysis suggests that although in some cases target mRNA translation can be repressed without 
detectable changes in mRNA levels, most mRNAs displaying strong (i.e., over 30%) reduction in 
protein levels also display detectable mRNA destabilization [61,62]. The mechanistic details and 
relative contribution of each process to gene silencing by miRs has been the object of intensive 
investigation, but several critical aspects remain to be resolved (reviewed by [60,63]). In spite of the 
undisputed relevance of the seed sequence in determining the miR-mRNA base pairing interaction, a 
recent report suggests that imperfect centered binding sites may be both common and functional in 
human cells [64]. The ability of a miRNA to interact with a target sequence is further influenced by the 
secondary structure of the target and the association of RNA binding proteins (RBPs) [65–67]. Once 
these interactions are established, the diverse nature of the outcomes on gene expression programs 
determines a whole new level of regulation that can have quite a profound impact on cell function 
and fate. 
4. microRNAs’ Biological Functions: Getting to the Heart of the Matter 
A basic knowledge of how miRNAs interact with their target mRNAs and the consequences of this 
interaction in terms of target gene expression is still one step away from understanding the biological 
impact of these regulators on cell fate and function. Again, the diversity of modes of action, complex 
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underpinnings of the system and in many cases, the technical difficulties associated with the required 
experimental studies impose significant limitations on the quest for understanding the function of miRs 
at the level of the organism. 
4.1. Regulation of Gene Expression Programs by microRNAs 
The presence of multiple target sites with different affinities and abundances within a given cell (or 
even on a single mRNA) creates a dynamic environment that will strongly influence the interaction 
kinetics between miRNA and mRNA. To make matters more complex, recent data has revealed the 
existence of several cellular RNA molecules that act as miRNA sponges to regulate their availability. 
These include pseudogene mRNAs [68], long-non-coding RNAs [69] and even previously unknown 
circular RNA species [70,71]. Together with the properties of the miR-mRNA interaction, this makes 
the sequence-based prediction of effective miRNA targets a complex problem that many groups have 
attempted to tackle with limited success. In particular, the integration of kinetic models into 
predictions will likely be fundamental for a robust prediction of functionally relevant mir-mRNA 
interaction (see discussion by [72]). As a corollary of all this, the outcome of a miR-mRNA interaction 
can be markedly different, ranging from full repression of gene expression through the reduction of 
target mRNA abundance to inconsequential levels (termed ‘switch targets’), to reduction of target 
abundance (or translation rates) to lower, yet functional levels (termed ‘tuning targets’), to apparently 
having no effect (termed neutral targets) [73]. 
Tremendous efforts have been made in recent years in order understand miRNA biology, with 
functional studies pointing to important roles played by miRs in the regulation of almost every cellular 
process. Additionally, the misregulation of miRNAs is often associated with human pathologies [74].  
In theory, a single miRNA can interact with hundreds of mRNA molecules and a specific mRNA 
molecule may be the target of multiple miRs. Therefore, miR-mRNA interactions can define complex 
regulatory networks that serve to coordinate entire gene expression programs. These networks may 
further involve intercellular interactions according, for example, to the reports that miRs are actively 
secreted in exosomes or are capable of intercellular movement through a gap junction dependent 
mechanism, like the ones present in heart cardiomyocytes [75]. The current knowledge of miRNA 
biology has further revealed complex regulatory events in which transcriptional factors and miRNAs 
interplay through positive and negative feedback loops in order to control gene expression programs 
that modulate cell fate and differentiation (Figure 3). 
4.2. Role of microRNAs in Cell Fate Decisions 
The observation that the miRNA biogenesis machinery, although required for vertebrate 
development, was not essential for cell survival and did not interfere with the early stages of body plan 
establishment led to the suggestion that the main role of miRs might be related to regulating the 
diversification of cell types within organs and tissues [76,77]. The first studies identifying miRNAs as 
regulators of lineage commitment in animals came from studies involving over-expression of tissue 
enriched and tissue specific miRs. The latter can be defined as miRs whose expression level in one 
tissue is 20 fold or more higher than in all other tissues [78]. The hematopoietic enriched miR-181 was 
the first to be shown to shift progenitor cell differentiation into the specific lineage where it is 
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abundant—B cells [79]. However, this study was specifically performed in the context of 
hematopoietic progenitors and did not provide significant insights into the underlying regulatory 
mechanisms. A more defined view of the power of miRs to shift gene expression programs into cell 
type specific programs came from the transfection of miR-124 and miR-1 into HeLa cells, followed by 
microarray analysis [80]. These miRs display a highly tissue specific expression pattern, with miR-124 
being preferentially expressed in the brain and miR-1 in the skeletal muscle and heart. The analysis of 
the impact of overexpressing these miRs in HeLa cells established for the first time that animal miRs 
can influence the abundance of over 100 target mRNAs through base-pairing interactions between the 
seed and the 3' UTR, as opposed to having only an effect on translation repression [80]. Furthermore, 
Lim and colleagues found that they could infer the tissue of origin of these miRs by simply comparing 
the gene expression profile of the transfected cells with the profiles of different human tissues. Indeed, 
the gene expression profile was significantly and specifically shifted towards the expression profile of 
the miRNA tissue of origin through the systematic silencing of genes that were not expressed in those 
tissues. This led to the proposal that miRs help define and maintain the different cell types of animals. 
This study was complemented by the analysis of the impact of inactivating miR-1 expression in 
Drosophila, which revealed the extent of conservation of miRNA functions [81]. miR-1 knock-out 
(KO) led to major alterations in myofiber structure and muscle growth, resulting in larval paralysis and 
lethality. Interestingly, this phenotype could be rescued by muscle specific expression of miR-1, 
reinforcing its tissue-specific nature. Later experiments involving the ectopic expression of miR-1 in 
mouse and human embryonic stem cells revealed that this miRNA is a strong promoter of mesoderm 
differentiation, displaying enhanced cardiomyocyte formation, while at the same time suppressing 
gene expression of other lineages [82]. Based on these results, the authors proposed for the first time 
that miRs could be used as tools to drive the differentiation of embryonic stem cells. Further studies 
have identified multiple miRs that act as regulators of cell fate, as reviewed by Ivey and Srivastava 
(2010) [83]. In addition to this, miRs have also been shown to play critical roles in the establishment of 
stem cell properties, in particular in the maintenance of the pluripotent state (reviewed by [84]).  
4.3. miRNAs as Critical Regulators of Stem Cell Properties 
Embryonic stem cells (ESCs) and tissue or adult stem cells are central mediators of tissue 
development and homeostasis, respectively. By definition stem cells have the property of asymmetric 
division, i.e., they divide and generate another cell with stem cell properties by self-renewal, and a cell 
committed to specialized functions through differentiation. The diversity of cell types that can be 
generated from such a self-renewing cell may range from unlimited (for the totipotent ESCs) to 
different degrees of pre-commitment in adult stem cells, which may thus be referred more 
appropriately as progenitor cells. ESCs were studied in depth for the role of miRs in the definition of a 
cellular identity and control of their characteristic properties. Inhibition of every miRNA present in the 
cell, by suppression of Dicer, led to an acute loss of proliferative potential and a failure to silence the 
embryonic cell program and differentiate [85]. ESCs have a defined miRNA profile with a limited 
number of expressed miRs, both in humans and in mice, that decrease as stem cells differentiate [85]. 
Interestingly, some of the identified miRs present in ESCs are involved in the negative regulation of 
cell proliferation and of the pluripotency factors Oct4, Nanog and Sox2. Overall, ESCs seem to 
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express miRs with antagonistic functions in the regulation of self-renewal and proliferation [84]. 
Depending on their balance, an ensuing cell fate decision will be made (Figure 4). In spite of being 
often viewed as ‘fine-tuners’ of gene expression or ‘robustness’ enforcers, recent studies have shown 
that a small number of stem cell specific miRs are ‘powerful’ enough to promote somatic cell 
reprogramming, reverting cells back to an ESC like state [86–88]. Conversely, some tissue-specific 
miRs have been shown to be able to direct trans-differentiation (i.e., the direct reprogramming of cell 
state without passing through an undifferentiated condition) [89,90]. These observations have placed 
miRs under the spotlight as emerging tools for the development of regenerative therapies (reviewed  
in [15,91]). 
Figure 4. miRNAs are master regulators of cell lineage commitment. In response to a 
given genetic switch, miRNAs can fine-tune the transcriptome to modulate cell 
proliferation and differentiation. By targeting positive or negative regulators of lineage 
specification, miRNAs act as rheostats that adjust the proteome required for the activation 
or repression of the genetic programs that provide robustness to cell fate decisions.  
 
4.4. Regulatory Feedback between miRNAs and Transcription Factors 
The properties that allow miRNAs to have such a robust impact on the definition of cellular gene 
expression programs, seem to stem from the interweaving of their post-transcriptional regulatory 
activities with core transcriptional networks that control cell fate and differentiation [83]. Although the 
specific modalities by which the two intersect can be quite diverse depending on the specific situation, 
a common theme of feedback and feed-forward loops between miRs and transcription factors, either 
counterbalancing or reinforcing cellular decisions, has clearly emerged. 
One of the first known examples of these regulatory loops involves the interplay of miR-1 and the 
cardiogenic and myogenic transcription factors (Figure 5). miR-1 is actually a member of an 
evolutionarily conserved family that in mammals is organized as three bicistronic TUs (Figure 3A).  
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miR-1 is encoded by two genes, miR-1-1 and 1-2, which are clustered with miR-133a-2 and miR-133a-1, 
respectively. These genes are under the control of the master cardiogenic and myogenic transcription 
regulators SRF, Mef2, MyoD and myogenin, thereby presenting both cardiac and skeletal muscle 
specific expression [34,92,93]. A third paralogous gene cluster encodes the miR-206/miR-133b pair, 
which is only expressed in the skeletal muscle. miR-1 and miR-133 are for the most part co-expressed 
and contribute to the establishment of a muscle specific gene expression program while having 
somewhat antagonistic roles in the control of proliferation and differentiation [94]. Indeed, while  
miR-1 is acknowledged to trigger differentiation of both mouse and human embryonic stem (ES) cells 
into the cardiomyocytes, miR-133 was found to act in partial opposition to miR-1, by promoting 
muscle progenitor expansion and preventing terminal differentiation [82]. Interestingly, both miR-1 
and miR-133 have been shown to be negative regulators of the same cardiogenic transcription factors 
that, in addition to promoting their expression, activate protein-coding genes involved in muscle 
function (e.g., sarcomere genes) [34,92,94,95]. The existence of multiple independent enhancers of the  
miR-1/133 genes and the negative feedback loop established between miRs and transcription factors 
allow fine-tuning of temporal-spatial control of gene expression, providing a means of reinforcing the 
cardiac and skeletal-muscle-specific programs during development and cell differentiation. 
Figure 5. Transcriptional regulatory networks controlled by miR-1 and miR-133 during 
cardiac muscle differentiation. In mammals, the duplicated miR-1/miR-133 locus is 
transcribed into a bicistronic transcript that is regulated by multiple independent upstream 
intronic enhancers. In the embryonic heart, expression of the miR-1/miR-133 locus is 
transcriptionally regulated by the myogenic transcription factors SFR, MYOCD and 
MEF2. By targeting the same transcription factors that regulate miR-1/miR133 expression 
and control cardiac progenitor cell proliferation and differentiation, miR-1 and miR-133  
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5. microRNAs in Heart Development 
The earliest studies on miRNA expression and function immediately suggested a prominent role in 
the cardiac tissue [96–99]. This initial hypothesis was to be supported by a growing number of studies 
that showed not only that the miRNA biogenesis machinery is required for normal heart development, 
but were also able to dissect the roles of specific miRNAs in the regulatory networks controlling the 
embryonic and post-natal steps of heart development. 
5.1. Requirement of the microRNA Machinery for Heart Development 
The first evidence for the role of miRs in heart development came from the study of knock-out 
animals targeting the core miRNA biogenesis machinery: Drosha, DGCR8, Dicer and Ago2 [100–104]. 
The use of mouse models is limited by the fact that the ablation of these essential proteins results in 
early embryonic lethality, preventing the analysis of the overall contribution of miRs to the 
cardiovascular system. Therefore, addressing the specific contributions of the miRNA pathway to heart 
development required the use of tissue/cell type specific knock-outs for these genes. Deletion of Dicer 
during early heart development has been achieved using Nkx2.5 driven recombinase expression [100,101]. 
These studies reported major defects in ventricular myocardium structure, cardiac outflow tract 
morphogenesis and chamber septation, in addition to pericardial edema. Deletion of Dicer at later 
stages in development using the cardiomyocyte specific promotor for the MHC/Myh6 gene resulted in 
early post-natal death associated to the presence of cytoskeletal defects and deregulation of proteins 
important for contractility, cardiac conduction, and calcium handling [102]. Dicer and Dgcr8 deletion 
in neural crest cells, which participate in the development of the cardiac outflow tract, revealed critical 
contributions of miRs for cell migration and patterning processes [103,104]. Interestingly, the 
observed defects strongly resembled the developmental abnormalities present in some human genetic 
disorders, including the Di George micro-deletion syndrome, which includes the genomic locus of the 
DGCR8 gene that is part of the canonical miRNA processing machinery [105]. Although the heart 
malformations associated with this syndrome have been proposed to result from haplo-insufficiency of 
the cardiogenic transcription factor Tbx1, also located in the Di George critical region [106,107],  
it is highly likely that part of these defects are in fact linked to perturbations in the miRNA 
biogenesis pathway.  
While suggesting an important role for miRs at all levels of regulation of the cardiac developmental 
program, from differentiation to morphogenesis, these approaches fail to identify the contributions of 
specific miRs, which require their targeted manipulation. Together with studies characterizing miRNA 
expression levels across tissues and developmental stages and in response to heart injury, the 
development of these functional approaches led to the identification of multiple miRs that play a 
role in heart development and response to injury, a topic that has been the subject of several recent 
reviews [94,108]. 
5.2. The miR-1/133 Family is a Critical Component of Cardiogenic Regulatory Networks 
Standing out among the miRs with roles in cardiac function is the highly conserved miR-1, 
originally identified in early studies in Drosophila and C. elegans and shown to be highly expressed in 
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the human and mouse heart and skeletal muscle [96–99]. As discussed above, miR-1 was later found to 
be encoded in two bicistronic clusters together with miR-133a, which displays the same overall 
expression pattern and is also a key regulator of muscle and cardiac cell differentiation.  
Zhao and colleagues where the first to demonstrate that miR-1 can influence heart development, by 
showing that miR-1 overexpression in the developing mouse heart down-regulates the cardiogenic 
regulator Hand2 and results in premature withdrawal of cardiomyocytes from the cell cycle [34]. 
Strikingly, deletion of the single miR-1 gene in Drosophila also resulted in a spectrum of defects in 
muscle and cardiac differentiation [81,109]. These studies revealed for the first time a specific role for 
tissue-specific miRs in the establishment of cell differentiation programs, showing that miR-1 is 
required to maintain muscle gene expression and suggesting a high degree of functional conservation 
between flies and mammals.  
Interestingly, miR-133 is also conserved in Drosophila, but it is not clustered with the single  
dm-miR-1 gene. Studies on the evolution of this miRNA family suggest that they became clustered in 
the early stages of chordate evolution, becoming linked to the GATA4/5/6 ancestral gene before the 
genome duplication events that occurred near the base of the vertebrate lineage [110]. The genomic 
duplication events at the base of vertebrate evolution therefore resulted not only in the appearance of 
the three cardiogenic GATA genes (GATA4, GATA5 and GATA6) but also created the miR-1/133 
gene family. One of the miR-1 paralogs was later converted into the skeletal muscle specific miR-206, 
roughly at the time of the teleost divergence [110]. Strikingly, the association between GATA-4 and 
the miR-206/133b gene cluster was lost during mammalian evolution, although it is still retained in all 
other vertebrates. It is, therefore, tempting to speculate that the evolution of the gene regulatory 
programs underlying the development of the mammalian heart, which involved the expansion and  
re-organization of the core cardiogenic transcriptional machinery [16], occurred in tight connection 
with the development of a miRNA dependent control layer.  
Further insights into the role of the miR-1/133 family in cardiac development were obtained 
through the generation of knock-out mice with targeted ablation of these miRs. miR-1 was one of the 
first miRs whose function was characterized by this approach [101,111]. In spite of its duplication, 
ablation of the 21 nt miR-1 sequence in the miR-1-2 gene using a targeted recombination strategy 
designed to replace it with a Neo-LacZ selection marker was reported to resulted in 50% embryonic 
lethality with ventricular septation defects (VSD)[101]. The surviving animals had normal heart 
morphologies but displayed heart hyperplasia associated to abnormal myocyte proliferation and 
cardiac conduction defects, with frequent sudden death during the first post-natal weeks. Similar 
results have been reported for a miR-1-1 KO using the same targeting strategy [112]. However, the 
apparent haplo-insufficiency of miR-1 in heart development has been questioned by more recent 
double KO mice, which do not show any embryonic lethality [113]. The key difference between this 
and the earlier studies is the removal of the positive selection cassettes. These sequence elements have 
been reported to cause transcriptional interference and could thereby affect the KO phenotype in a 
non-specific manner [114]. An older study using knock-outs for miR-133a-1 and miR-133-a2 with 
removal of the selection markers also supports the redundancy of these genes during heart 
development, as only the double knock-out mice displayed detectable cardiac phenotypes [115]. 
Finally, a more recent targeted ablation of a single miR-1/133 cluster did not show any significant 
developmental or cardiac defects, which were only observed upon deletion of both clusters [116].  
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These more recent models also raise interesting questions regarding the role of the miRs-1/133 
during heart development. Indeed, Wei and colleagues do not report any embryonic lethality in the 
mir-1 dKO mice [113]. For the miR-133 dKO animals, albeit a modest reduction in viability is 
observed during embryonic development, along with a high number of VSD related deaths soon after 
birth (day P0/P1), about half of the mice hearts developed with a relatively normal morphology [115]. 
Only the miR-1/133 dKO displayed significant cardiac abnormalities during embryonic development, 
with no animal surviving past embryonic day E10.5 [116]. This is in sharp contrast with the previously 
described defect of miR-133a dKO mice, which becomes apparent only at later stages [115]. The 
complete loss of miR-1/133a did not interfere with formation of the primary heart tube, but affected 
maturation and further specification of embryonic cardiomyocytes during expansion of the compact layer 
of the myocardium. 
5.3. microRNAs Play a Critical Role in the Cardiac Fetal-to-Adult Switch 
In spite of the fact that the available KO mice for the mR-1/133 family present some discrepancies 
in the observed phenotypes, the requirement for these miRs for an appropriate transition from the fetal 
to a more mature/adult cardiac gene expression program is extremely consistent. Interestingly, the lack 
of miR-1/miR133 seems to affect multiple cellular pathways required for this transition. These include 
marked changes in the cardiac contractibility apparatus, with a switch from fetal specific to adult 
isoforms of several sarcomeric proteins, and the silencing of smooth muscle proteins expressed early 
during cardiomyocyte differentiation, which appears to be regulated by both miR-1 and miR-133. In 
addition, this switch is associated to significant changes in energy metabolism, moving from glycolytic 
pathways in fetal cardiomyocytes to fatty acid oxidation in the adult heart, which seems to be also 
affected in the absence of miR-1. Finally, the cessation of cell proliferation, a hallmark of the fetal to 
adult transition, was also reported to be affected in four of these mouse models, where cardiomyocytes 
division was observed to occur late after birth [101,113,115]. Thus, the available data support the view 
that miR-1 and miR-133 play a critical synergistic role in the suppression the cardiac fetal gene 
program and enforcement of adult skeletal muscle properties, driving cardiac maturation.  
Interestingly, several other miRs are reported to play critical roles in the fetal to post-natal cardiac 
switch. These include the so called ‘myomiRs’, mir-208a, miR-208b and miR-499, which are 
encoded as introns of the α, β and 7b myosin heavy chain (MHC) encoding genes Myh6, Myh7 and 
Myh7b [94]. The β-MHC is expressed in the fetal heart, switching to the α-MHC in the adult heart. 
This switch involves a regulatory circuitry among the MyomiRs and their host myosins that appears to 
be operative specifically in the adult heart [117]. Additionally, cardiac postnatal development is 
marked by alternative splicing transitions from embryonic to adult cardiac protein proteins, 
coordinated for the most part by the CUBGP and ETR-3-like factor (CELF) family of splicing 
regulators. These proteins have in turn been shown to be directly regulated by miRs-23a/b, which 
coordinate a whole alternative splicing network during post-natal development [118]. Finally, the 
upregulation of the miR-15 family has been suggested to be a key regulatory event linked to the 
terminal exit of cardiomyocytes from cell cycle during the post-natal period [119]. This critical role of 
miRs in the establishment of a robust post-natal cardiac gene expression program is further supported 
by studies where the targeted post-natal deletion of Dicer was performed in the mouse heart, leading to 
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strong re-expression of fetal genes along with a marked hypertrophic response [120]. Conversely, the 
cardiac response to stress is marked by the aberrant expression of multiple miRs, in many cases 
associated with a re-enactment of the fetal gene expression program [121,122]. 
6. Heart Regeneration: A microRNA Connection to the Lost Link	
The heart is one of the mammalian organs with less regenerative potential [13,123–125]. As a 
consequence, heart function is significantly impaired by cardiac injury and aging, representing one of 
the most significant public health problems. This characteristic of the mammalian heart is in stark 
contrast, not only with the regenerative potential of many other tissues such as liver, gut, muscle or 
bone, but also with the cardiac regeneration abilities of other vertebrates, like amphibians or fish. 
Zebrafish, for example, can easily regenerate large surgical amputations of the cardiac apex, 
corresponding to about 20% of the total ventricular mass. This regeneration has been recently shown to 
occur mainly through cell division of mature cardiomyocytes [126,127], which in the adult mammalian 
heart display only residual proliferative activity (reviewed in [13]). Understanding the origin of these 
differences and how they connect to the conserved underlying genetic circuitry established by miRs 
and transcription factors can provide important insights into the development of regenerative therapies 
for human heart disease. 
6.1. Adult Cardiac Progenitor Cells under the Control of microRNAs Provide a Limited Source  
of Renewal	
The adult mammalian heart has been traditionally considered to be a post-mitotic organ because in 
classical histology studies, cardiomyocytes were never seen to divide (although they do undergo DNA 
replication). Two clinical observations first raised the possibility that there is cardiomyocyte renewal 
during human adult life. First came the observation that after myocardial infarction there are dividing 
cardiomyocytes [128]; second biopsies from human heart transplants with donor recipient sex 
mismatch were shown to harbor newly formed cardiomyocytes from the recipient [129]. A later study 
used the rise of Carbon 14 levels in the atmosphere due to the test atomic explosions that took place 
during the cold war, to date the DNA from human biopsies and calculate the renewal rate of 
cardiomyocytes during the human lifespan [124]. This study confirmed the existence of cardiomyocyte 
renewal, suggesting an age-dependent rate ranging from 1% per year at 20 to 0.4% at 75. These 
observations did not address whether this renewal involves the cell cycle re-entry of cardiomyocytes or 
rather results from the proliferation of progenitor cells. Supporting the second hypothesis, cardiac 
resident cells identified by the stem cell membrane markers c-kit, Sca-1, MDR1, were isolated from 
both human and mouse adult hearts. These cells are clonogenic, self perpetuating, can differentiate into 
all cardiac cell lineages and regenerate myocardium [123,130–133] identifying them as true adult 
cardiac progenitors (CPs). Resident cardiac progenitor cells have been shown to participate in the 
maintenance of normal heart homeostasis following a clonal differentiation pathway [134]. 
Interestingly, genes that control cardiac development are active in CPs and their differentiation process 
seems to replicate the embryonic program (reviewed by [21]). However, unlike embryological cells 
developing into cardiomyocytes, for which once the process begins, it inexorably leads to the final 
phenotype, these adult progenitors manage to become stuck in an intermediate stage; both the 
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mechanisms that stop and restart them are unknown, as well as the pathways that regulate their 
differentiation into the different cardiac cell types. As expected, miRNA profiling studies suggest that 
the CP phenotype is strongly influenced by these regulatory molecules. Indeed, human and mouse 
adult CPs express a subset of miRs that is clearly distinctive from cardiac embryonic, neonatal and 
mesenchymal progenitor cells, as well as from mature cardiomyocytes. The differentially expressed 
miRs are highly linked to the regulation of proliferation and differentiation processes [135–137]. 
Furthermore, the manipulation of some of these miRs in vitro (miR-1 and miR-499) and in vivo (the 
miR-17/92 cluster), was shown to be able to modulate CP cell fate [135,136] (Figure 6). Studies in rats 
have suggested that CP cells can be locally induced to proliferate and differentiate, contributing to a 
reversal of age and injury phenotypes [138]. Interestingly, the ability of CP-derived cardiomyocytes to 
fully mature and integrate into the functioning heart in vivo was shown to be modulated by miR-499, which 
seems to be transported through gap junctions from connected post-mitotic cardiomyocytes [139].  
The clear demonstration that the post-natal heart retains some proliferative potential has generated 
new prospects in the field of cardiac regeneration. The ideal regenerative therapy would essentially be 
able to take advantage of this potential in situ and potentiate the progenitor-based renewal that is still 
present in the adult heart. An alternative approach would be to try to recapture the cardiomyocyte 
proliferation status of the embryonic/early post-natal period into adult life.  
Figure 6. miRNAs in the definition of cardiac cell fate. Niches of cardiac stem cells in the 
postnatal heart have the potential to differentiate into several cellular lineages that compose 
the heart. miRNAs can impact on heart regeneration by modulating the cellular fate of 
these resident cardiac progenitor cells and other cardiac cell types, in particular cardiac 
muscle cells and cardiac fibroblasts. Heart regions are colored according to their 
developmental origin: red—first heart field; green—second heart field; brown—both heart 
fields. See text for details.  
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6.2. Persistence of Cardiomyocyte Division after Birth: Is the Key to Regeneration Locked away by 
microRNAs?	
Cardiac regeneration in the zebrafish occurs mainly through the direct division of cardiomyocytes. 
Unlike mammalian cardiomyocytes, which undergo a final round of division that generates a  
bi-nucleated cell and from then on cease to perform cytokinesis and tend to become increasingly 
polyploid, zebrafish cardiomyocytes remain mononucleated and seem to be easily able to re-enter 
the cell cycle [12]. Interestingly, recent studies have suggested that the mouse heart also retains 
significant regenerative capacities during the first post-natal week [10]. Porrello and colleagues 
reported that when the ventricle apex of the heart was amputated in 1 day-old mouse pups (P1), the 
heart underwent full regeneration without scar formation, similar to adult zebrafish. When similar 
experiments were performed at P7, the regenerative potential was found to be lost. Cell lineage tracing 
studies showed that this regeneration is accomplished through cardiomyocyte division, in contrast with 
the progenitor dependent cell renewal observed in adult mouse hearts [10,13]. A more recent study, 
however, did not find the same evidence for complete regeneration and reported a reduced level of 
cardiomyocyte division after injury [140], generating a debate over the origins of the healing ability 
of the neonatal heart [141,142]. Nevertheless, a recent study in humans has shown that significant 
rates of cardiomyocyte division are present during the first year of life and can be detectable in young 
humans up to 20 years old [125]. Therefore, it seems that the mammalian post-natal cardiac switch 
eliminates the set of more primitive, embryonic characteristics that support regeneration in lower 
vertebrates. Not surprisingly, considering the prominent role played by miRs in the regulation of this 
switch, Porrello and colleagues [143] have recently shown that inhibition of the miR-15 family can 
increase proliferation in the adult mouse heart, leading to improved cardiac function after injury.  
With these observations in mind, Eulalio and colleagues recently performed a high-throughput 
functional screen to identify miRs able to induce the proliferation of neonatal rat cardiomyocytes using 
a whole genome miRNA library [144]. The screen identified 204 miRs that strongly increased both 
DNA synthesis and cytokinesis, of which 40 induced the same effect in mouse neonatal 
cardiomyocytes, which are known to significantly less proliferative potential. Interestingly, the top 10 
miRs promoting cardiomyocyte proliferation in rats were not the same that induced the most efficient 
proliferation in mouse cells, suggesting that relevant species-specific effects may occur. Two of these 
miRs (hsa-miR-590 and hsa-miR-199a) were further tested and shown to promote cardiomyocyte 
proliferation in the heart of adult animals, stimulating marked cardiac regeneration after myocardial 
infarction with almost complete recovery of cardiac functional parameters. These results suggest that 
selected miRs can be used as therapeutic tools to revert the cardiomyocyte cell cycle arrest with a 
positive impact in heart regeneration (Figure 6). 
6.3. Reprograming of Cardiac Fibroblasts to Functional Cardiomyocytes	
A third, more radical hypothesis for in situ regeneration is to target cardiac fibroblasts to promote 
the formation of ventricular cardiomyocytes. 
The potential of this idea is underscored by some of the differences in heart structure and response 
to injury between mammals and other vertebrates with significant cardiac regenerative abilities. In 
Cells 2014, 3 1015 
 
contrast with lower vertebrates, the mammalian heart is part of a high-pressure system that has to deal 
with significant forces. In agreement with this, the mammalian and lower vertebrate hearts present a 
significantly different histological organization of the tissue, including a complex network of 
fibroblasts. Although relatively rare in amphibian and fish, these are the most abundant non-muscle 
cells in mammals, representing 50% of the cells in the heart. The myocardium of these lower 
vertebrates is actually much simpler and resembles the embryonic trabecular heart of mammals [145].  
Upon cardiac injury, the mammalian heart will respond with a strong fibrotic reaction, leading to 
the quick formation of scar tissue. Bleeding from the heart in a high-pressure circulatory system, 
which is practically unique to higher vertebrates, can seriously jeopardize survival. Accordingly, some 
authors have suggested that the limited regeneration potential of the mammalian heart is linked to an 
evolutionary prioritization of hemostasis and fibrosis [145]. The extensive cardiac fibroblast network 
of the heart may therefore contribute to create an unfavorable environment for heart regeneration. 
Strikingly, earlier evidence suggests that even in regenerative animals, fibrosis and regeneration are 
competing events that need to strike a balance [146]. These observations point to cardiac fibroblasts as 
important targets in the development of regenerative therapies, either focusing on the control of the 
fibrotic response, or through the promotion of fibroblast trans-differentiation into cardiomyocytes. 
This second approach would not only contribute to tip the balance away from fibrotic repair but would 
also promote regeneration by increasing the rate of cardiomyocyte renewal [147].  
In agreement with their pervasive functions, miRNAs have also been shown to regulate the fibrotic 
responses of cardiac fibroblasts. In particular, miR-29, which is down-regulated in response to cardiac 
injury, has been shown to inhibit the expression of fibrotic genes [148], while miR-21, which is 
upregulated in response to cardiac stress, has been proposed to promote it [149,150], although a  
miR-21 KO mouse model raises questions on the essential nature of this response [151]. 
Finally, although trans-differentiating fibroblasts to cardiomyocytes may sound like a radical 
approach, the fact is that recent studies have shown it to be possible in vivo [152,153]. The possibility 
of reprograming fibroblasts into muscle cells has been demonstrated over 25 years ago by the forced 
expression of the muscle transcriptional regulator MyoD [154]. Similarly, these recent studies used 
retroviral vectors to induce the expression of cardiogenic transcription factors in cardiac fibroblasts  
in vivo, resulting in the differentiation of these cells into mechanically coupled cardiomyocytes. 
Interestingly, cardiac regeneration in zebrafish has recently been shown to involve a ‘natural’ 
reprogramming event whereby atrial cardiomyocytes trans-differentiate into ventricular cells [155]. It is 
worth noting that these studies were performed in zebrafish embryos and therefore it remains to be seen 
if such a phenomenon could be of significance in another context. Although the potentiation of similar 
processes in the mammalian heart may therefore not be such a far-fetched approach to promote 
sustained regeneration after injury, it is also worth noting that the consequences of depleting some of 
the adult heart population of fibroblasts or atrial cardiomyocytes in favor of ventricular 
cardiomyocytes are not clear. 
Although it has been argued that miRNAs act mostly as a secondary fail safe mechanism in the 
definition of cell fate, conferring accuracy and robustness to the underlying gene expression  
programs [46], recent studies have highlighted the tremendous power of these molecules to promote 
differentiation into specific cell types, including reprogramming of fibroblast into cardiomyocytes [15,90].  
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The observation that defined sets of transcription factors could be used to reprogram fibroblasts to 
pluripotent stem cells, which could then be differentiated into the cell type of interest, opened the 
conceptual possibility for direct somatic reprogramming to a desired cell type. The conversion of 
fibroblasts to cardiomyocytes without an intermediate de-differentiation step was first reported in vitro 
by the Srivastava group [156]. This work was later followed by two studies that demonstrated the 
feasibility of the approach in vivo and reported the functional integration of the newly formed 
cardiomyocytes into the heart with positive effects in the recovery of myocardial infarction [152,153]. 
The demonstration that sets of miRs can induce reprogramming of somatic cells to pluripotency [86] 
established a similar parallel that still has to be systematically explored. The first report of an 
equivalent reprogramming event used an ‘educated guess’ approach to test the individual and 
combined effects of six miRs with reported cardiac functions (miR-1; miR-126-3p; miR-133a;  
miR-138, miR-206; miR-208a) to induce fibroblast trans-differentiation [90]. This led to the 
identification of an optimal combination of three miRs (miRs-1, 133, 208), together with miR-499, to 
induce efficient trans-differentiation of cardiac mouse fibroblasts both in vitro and in vivo (Figure 6). 
Furthermore, in order to confirm that this effect did not come from the activation of cardiac progenitor 
cells, the ability of this set of miRs to induce cardiomyocyte formation was tested on mouse tail 
fibroblasts, confirming the nature of the postulated cell conversion. 
7. Conclusion and Future Perspectives	
The past few years have generated revolutionary insights not only into our understanding of the 
genetic regulatory programs that control cell function and fate in the context of heart development, but 
also in our ability to manipulate these programs for therapeutic purposes. Central to these 
developments is the identification of a previously hidden, non-coding layer for gene expression 
regulation, of which miRs represent a critical part. Standing together with novel major advances 
regarding our understanding of stem and progenitor cell function and regulation and of cellular 
reprogramming events, these progresses herald a new era for the development of regenerative 
therapies, with particular focus on the heart. Our current understanding suggests that the mammalian 
heart contains an untapped potential for regeneration that could be engaged to promote new therapies 
for cardiac injury. Coupled to their physical characteristics, miRs stand as prime candidates for the 
development of effective tools to promote such in situ regeneration. miRNA mimics or inhibitors can 
be easily synthesized and in animal are easily administered to cells via lipid-based transfection with 
low toxicity models. Moreover, the small size of a single miRNA allows the easy packing of distinct 
molecules as required to induce the desired cell response. Although there is still a long way ahead, the 
recent advances can easily make us believe in a not so far away future, where such therapies will 
become available for patients. This will however require a deeper understanding of the precise 
functions played by specific miRNAs in cardiac cell differentiation that will not only require the 
profiling of miR expression under various developmental, functional, mutant and disease conditions, 
but also systematic studies focused on target identification based on miRNA-mRNA interactions. The 
recent developments in deep-sequencing, namely in single-cell sequencing, will provide an important 
technological basis for such studies, in particular by supporting a much needed characterization of cell 
type specific expression and function of miRNAs. 
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